Rights and permissions
About this article
Cite this article
Donepezil study underpowered, say Eisai and Pfizer. Pharmacoecon. Outcomes News 457, 2 (2004). https://doi.org/10.2165/00151234-200404570-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200404570-00002